Industry Reports

Amgen has announced the acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom, in a deal valued at up to $840 million. The…
Read More...

Takeda Pharmaceutical Company has entered into a global collaboration and license agreement with Halozyme Therapeutics to use Halozyme’s proprietary ENHANZE® drug delivery technology…
Read More...

Inductive Bio, an AI-driven drug discovery company known for developing virtual chemistry laboratories, has been awarded up to $21 million to lead a groundbreaking project aimed at…
Read More...

Alkermes plc and Avadel Pharmaceuticals have agreed to revised terms for Alkermes’ acquisition of Avadel, increasing the total potential value of the deal to $22.50 per share. The new…
Read More...

Novartis announced that it has successfully completed the acquisition of Tourmaline Bio, Inc., making the biotechnology company an indirect wholly owned subsidiary of Novartis.…
Read More...

Reunion Neuroscience, a clinical-stage biopharmaceutical company focused on next-generation psychedelic-inspired therapies for mental health, announced the final closing of its Series A…
Read More...

The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to riliprubart, an investigational monoclonal antibody developed by Sanofi, for the…
Read More...

Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new therapeutics that target shared underlying…
Read More...

Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, launches from stealth having raised a total of $140 million (£107…
Read More...

Pfizer Inc. announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for…
Read More...

AIRNA, a biotech company pioneering RNA editing therapeutics to transform the lives of patients with rare and common conditions, announced the closing of an oversubscribed $155 million…
Read More...

AbbVie announced that it has completed its acquisition of ImmunoGen. With the completion of the acquisition, ImmunoGen is now part of AbbVie. "Together with ImmunoGen, we have the…
Read More...

Sanofi and Inhibrx, Inc. (“Inhibrx”), a publicly traded clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, have…
Read More...

Esperion Therapeutics, Inc. and Daiichi Sankyo Europe GmbH (DSE) the European headquarter organization of the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd. announced today a…
Read More...

Beijing Avistone Biotechnology Co., Ltd. (also referred to as Avistone Biotechnology or Avistone), an innovative biotechnology company focused on precision oncology therapeutics,…
Read More...

Apollo Therapeutics, a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines through a hub-and-spoke approach, today announces the close…
Read More...

Kyverna Therapeutics, a clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune diseases, today announced the close of an…
Read More...

Solu Therapeutics, a precision-medicine company developing therapeutics to eliminate disease-driving cells, founded by Longwood Fund, announced the closing of an oversubscribed $31…
Read More...

Kriya Therapeutics, Inc. announced the addition of over $150 million in capital committed as part of its Series C Financing, bringing the total Series C round to over $430 million.…
Read More...

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, and its wholly-owned commercialization subsidiary Tonix Medicines, Inc. (Tonix Medicines), announced it has completed…
Read More...